Subscribe
T. Schneider / Shutterstock.com
17 April 2025NewsBig PharmaLiz Hockley

AstraZeneca unit faces class-action suit over alleged Soliris monopoly

Massachusetts lawsuit claims subsidiary of UK pharma company unlawfully re-patented eculizumab, resulting in overpayments of more than $2 billion.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
AstraZeneca fends off diabetes generic, for now
10 April 2025   Decision overturns earlier decision allowing generic drug maker to launch version | Dispute centres on $300-million dollar treatment for diabetes, chronic heart failure and kidney disease—currently protected by a challenged SPC.


Editor's picks

Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025

Editor's picks

Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025

More on this story

Big Pharma
AstraZeneca fends off diabetes generic, for now
10 April 2025   Decision overturns earlier decision allowing generic drug maker to launch version | Dispute centres on $300-million dollar treatment for diabetes, chronic heart failure and kidney disease—currently protected by a challenged SPC.

More on this story

Big Pharma
AstraZeneca fends off diabetes generic, for now
10 April 2025   Decision overturns earlier decision allowing generic drug maker to launch version | Dispute centres on $300-million dollar treatment for diabetes, chronic heart failure and kidney disease—currently protected by a challenged SPC.

More features

Fenwick establishes new Boston office with trio of IP partners from Cooley
How pharma should prep for the six-bill avalanche from Congress
USPTO speeds up patent issuance amid widespread agency changes
Lathrop GPM adds portfolio management specialist
Fed Circ decides fate of Orange Book patent covering blockbuster J&J schizophrenia drug
Failure to make findings of fact adds twist to battle over Eliquis in Ireland
Novo Nordisk, Bayer, GSK among giants accused in drug delivery suits
BMS notches legal win and FDA nod